Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.

Pierfranco Conté; Maria Vittoria Dieci; Giancarlo Bisagni; Michelino De Laurentiis; Carlo Tondini; Peter Schmid; Gian Luca De Salvo; Giacomo Moratello; Valentina Guarneri

doi:10.1200/jco.2020.38.15_suppl.tps598

Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.

Identifier:nobleid.org/w1/20260515/82BE5CDF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/82BE5CDF.svg?ark=w1%2F20260515%2F82BE5CDF)](https://nobleid.org/work/w1/20260515/82BE5CDF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Pierfranco Conté

Maria Vittoria Dieci

Giancarlo Bisagni

Michelino De Laurentiis

Claim authorship of this work

Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.

Identifier:nobleid.org/w1/20260515/82BE5CDF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/82BE5CDF.svg?ark=w1%2F20260515%2F82BE5CDF)](https://nobleid.org/work/w1/20260515/82BE5CDF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Pierfranco Conté

Maria Vittoria Dieci

Giancarlo Bisagni

Michelino De Laurentiis

Claim authorship of this work